Cargando…

CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner

Great progress has been made in the field of tumor immunotherapy in the past decade. However, the therapeutic effects of immune checkpoint blockade (ICB) against ovarian cancer are still limited. Recently, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6i) has been reported to enhance antitu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qian-Feng, Li, Jia, Jiang, Kuo, Wang, Rui, Ge, Jun-li, Yang, Hong, Liu, Shu-Juan, Jia, Lin-Tao, Wang, Lei, Chen, Bi-Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482823/ https://www.ncbi.nlm.nih.gov/pubmed/32929370 http://dx.doi.org/10.7150/thno.44871

Ejemplares similares

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Ding, Naiqing, et al.
Publicado: (2019)

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
por: Arce Vargas, Frederick, et al.
Publicado: (2017)

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022)

Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
por: Wei, Huafeng, et al.
Publicado: (2013)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
por: Liu, Peng, et al.
Publicado: (2022)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal
por: Wang, Zhenqing, et al.
Publicado: (2021)

Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis
por: Guan, Xin, et al.
Publicado: (2022)

Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade
por: Ju, Fei, et al.
Publicado: (2022)

Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade
por: Ocadlikova, Darina, et al.
Publicado: (2021)

Glutathione Pulse Therapy: Promote Spatiotemporal Delivery of Reduction‐Sensitive Nanoparticles at the “Cellular Level” and Synergize PD‐1 Blockade Therapy
por: Dong, Songtao, et al.
Publicado: (2022)

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
por: Fang, Douglas D., et al.
Publicado: (2019)

CDK4/6i enhances the antitumor effect of PD1 antibody by promoting TLS formation in ovarian cancer
por: Feng, Wangyou, et al.
Publicado: (2023)

CaCO(3) powder-mediated biomineralization of antigen nanosponges synergize with PD-1 blockade to potentiate anti-tumor immunity
por: Su, Runping, et al.
Publicado: (2023)

A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
por: Tondini, Elena, et al.
Publicado: (2019)

Intravesical VAX014 Synergizes with PD-L1 Blockade to Enhance Local and Systemic Control of Bladder Cancer
por: Tsuji, Shingo, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
por: Ali, Lestat R., et al.
Publicado: (2023)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma
por: Voce, David J., et al.
Publicado: (2021)

PPARγ inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner
por: Wu, Bogang, et al.
Publicado: (2020)

C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer
por: Zhang, Chen, et al.
Publicado: (2023)

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
por: Zeng, Mei, et al.
Publicado: (2018)

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
por: Lu, Lei, et al.
Publicado: (2014)

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice
por: Qin, Wan, et al.
Publicado: (2020)

Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade
por: Xue, Ying, et al.
Publicado: (2023)

Correction: PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
por: Ali, Lestat R., et al.
Publicado: (2023)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2023)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma
por: Zhang, Wei, et al.
Publicado: (2023)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer
por: Wang, Ying, et al.
Publicado: (2020)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

Immunogenic Cell Death Inducing Fluorinated Mitochondria‐Disrupting Helical Polypeptide Synergizes with PD‐L1 Immune Checkpoint Blockade
por: Jeong, Seong Dong, et al.
Publicado: (2021)

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity
por: El-Sayes, Nader, et al.
Publicado: (2022)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner
por: Alexandrova, Evguenia M, et al.
Publicado: (2017)

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine
por: Walsby, Elisabeth, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_65tjiih1l22nsdhdj1o7g4p990